在共价有机框架/金属有机框架纳米反应器中的自我放大缺氧级联,用于协同作用的癌症治疗
Chengcai He1, Ye Zhang1, Xiaozhen Liu1
1College of Pharmacy, Key Laboratory of Innovative Drug Development and Evaluation, Hebei Medical University, Shijiazhuang 050017, China.
Journal of colloid and interface science
|December 7, 2025
概括
一个新的纳米平台加剧瘤缺氧,以增强癌症治疗. 这种低氧反应系统放大了药物释放,并结合了多种疗法,以有效地抑制具有低毒性的瘤.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 在瘤学瘤学.
背景情况:
- 瘤缺氧是癌症进展和治疗耐药性的关键因素.
- 低氧激活前期药物 (HAP) 是有前途的,但需要足够的低氧才能有效.
- 现有疗法在瘤中抗击不足的低氧水平.
研究的目的:
- 设计一种对缺氧反应的纳米平台,以加剧瘤缺氧并触发自我放大治疗级联.
- 通过提高其激活和有效性来克服HAPs的局限性.
- 开发一种多模式的治疗策略,以改善瘤抑制.
主要方法:
- 使用基共价有机框架 (p-COFs) 和基于铜的金属有机框架 (Cu-MOFs) 构建了一个纳米平台 (COF@MOF/TH-302@HA).
- 装有低氧激活前药TH-302,并涂上氨酸以向瘤.
- 利用近红外激光触发光热疗法 (PTT) 和光动力疗法 (PDT),创建反循环以增强缺氧和药物释放.
主要成果:
- 在激光照射后,纳米平台有效地加强了瘤缺氧.
- PDT诱导的氧气消耗放大了缺氧,加速了Cu-MOF降解和TH-302的释放.
- PTT增强了Cu2+介导的化学动力学疗法,从而产生了协同作用的抗瘤作用.
- 在试验室和体内证明有效的瘤抑制,系统毒性最小.
结论:
- 开发的纳米平台成功地利用瘤缺氧进行自我增强的协同疗法.
- 这一策略整合了化学动力学疗法,PTT,PDT和HAP化疗,以获得强大的抗癌活性.
- 这些发现提出了一种新的方法来克服由瘤缺氧驱动的治疗阻力.
更多相关视频
相关概念视频
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
02:53Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
01:46Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K